Pulmonary Arterial Hypertension (PAH) Market Estimates, Share, Vendors, Growth Rate Forecast 2014-2025

Pulmonary Arterial Hypertension (PAH) Market Estimates, Share,
Vendors, Growth Rate Forecast 2014-2025
“Pulmonary Arterial Hypertension (PAH) Market size was valued at USD 5.0
billion in 2015 and is anticipated to reach USD 8.7 billion by 2025. Pulmonary
arterial hypertension (PAH) is a type of high blood pressure that occurs in the
right side of the heart and in the arteries that supply blood to the lungs.”
The global Pulmonary Arterial Hypertension (PAH) Market size was valued at USD 5.0 billion in 2015 and is
anticipated to reach USD 8.7 billion by 2025. Pulmonary arterial hypertension (PAH) is a type of high blood
pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. These
arteries are called pulmonary arteries. PAH occurs when the pulmonary arteries thicken or grow rigid. PAH is
one of the five groups of pulmonary hypertension, classified by the World Health Organization (WHO).The
market for PAH is growing moderately due to newer launches of pipeline drugs that target different pathways
to suppress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of
patients undergoing treatment.
Globally the PAH market is segmented on the basis of Drug class, Surgery, and region. On the basis of Drug class,
the global PAH market is classified into Endothelin Receptor Antagonists (ERAs) (Tracleer, Opsumit, Letairis)-
These medications reverse the effect of endothelin, a substance in the walls of blood vessels that causes them
to narrow; Prostacyclin and Prostacyclin Analogs- were the first medications approved by the U.S. FDA for the
treatment of PAH. Phosphodiesterase-5 (PDE-5) V Inhibitors, Sildenafil, and Tadalafil- Revatio, Viagra, Cialis, etc.
These drugs work by opening the blood vessels in the lungs to allow blood to flow easily. These drugs have
superiority over existing therapy options with respect to the therapeutic efficacy, route of administration, and
side-effects.
Request Sample Copy of this Market Research @
https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market/request-sample

A new drug called Uptravi (selexipag), which is a selective IP prostacyclin receptor agonist, is expected to be
launched in 2016 and is likely to drive growth of the prostacyclin and prostacyclin analogs market. The rising
sales of these newly-approved therapeutic agents are likely to contribute to the overall revenue of the market.
Globally, regulatory bodies have granted an Orphan Drug Designation (ODD) status to all those drugs intended
to diagnose and treat or cure a rare disease. In the U.S., the Orphan Drug Act (ODA) encourages pharmaceutical
industries to develop orphan drugs by offering benefits such as tax credits, research grants, and orphan drug
exclusivity of seven years. These benefits are escalating the development, manufacturing, and marketing of
drugs intended to treat PAH, thereby driving market growth.
On the basis of surgeries, the global PAH market is classified into Atrial Septostomy- This is an open heart
surgery; in which surgeon will create an opening between the upper left and right chambers of your heart to
relieve the pressure on the right side of heart. Transplantation- Lung or heart-lung transplant might be an option
especially for younger people who have idiopathic pulmonary arterial hypertension.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market
Geographically, PAH market is segmented into North America, Europe, Asia Pacific, Latin America, MEA, and
Rest of the World. North America held the maximum share of market for PAH in terms of revenue in 2013, which
is then followed by Europe. These two developed regions are expected to witness substantial growth during the
forecast period, due to the recently approved PAH drugs in the market and the products that are anticipated to
receive approval during the next few years. In the Asia Pacific region, Japan, China, India, Australia, and New
Zealand exhibit immense opportunities for the companies operating in the PAH market.
The low level of awareness regarding the diagnosis and treatment of PAH is one of the prime reasons restraining
the market growth in MEA and rest of the world. The patent expirations of major PAH drugs along with the
availability of generic drugs are expected to adversely affect the overall revenue of the market. Some of the
major players in the market are Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc.,
GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc. and United Therapeutics Corporation are the key
players operating in the global PAH market.
Market Segmentation
Global PAH Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators

• ERA
• PDE-5
PAH Regional Outlook (Revenue, USD Million, 2014 - 2025)
• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• Asia Pacific
• Japan
• China
• Latin America
• Brazil
• Mexico
• MEA
• South Africa
See More Reports of this Category by Million Insights @
https://www.millioninsights.com/industry/healthcare

Get in touch
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our
representatives strive to understand diverse client requirements and cater to the same with the
most innovative and functional solutions.
Contact Person:
Ryan Manuel
Research Support Specialist, USA
Email: ryan@millioninsights.com
Global Headquarters
Million Insights
Felton Office Plaza 6265 Highway 9 Felton, California 95018, United States
Phone: 1-408-610-2300
Email: sales@millioninsights.com
Asia Pacific
Million Insights
Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016
India
Phone: 91-20-65300184